Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

Practical Neurology

Volumn 10, Issue 4, 2010, Pages 202-207

  Mitchell, Alex J ^a   Monge Argiles J A ^b   Sanchez Paya J ^b  

^a Leicester Royal Infrmary ^*  (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; DIAGNOSTIC AGENT; PEPTIDE FRAGMENT; TAU PROTEIN;

CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; HUMAN; PATHOLOGY; PREDICTIVE VALUE; REVIEW;

AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; DEMENTIA; DISEASE PROGRESSION; HUMANS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 77955761176     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/jnnp.2010.217778     Document Type: Review

References (28)

1. Luck T, Riedel-Heller SG, Hanna Kaduszkiewicz, et al. Mild cognitive impairment in general practice: age-specif c prevalence and correlate results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). Dement Geriatr Cogn Disord 2007;24:307-16.
2. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119:252-65.
3. Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology 2006;67:229-34.
4. Mitchell J, Arnold R, Dawson K, et al. Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm. J Neurol 2009;256:1500-9.
5. Waldemar G, Dubois B, Emre M, et al. EFNS. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
6. Andreasen N, Sjögren M, Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 2003;4:147-55.
7. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer's disease- perspectives for diagnosis, prediction of outcome and ref ection of biological activity. J Neural Transm 2004;111:247-72.
8. Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer's disease- perspectives for diagnosis, prediction of outcome and ref ection of biological activity. J Neural Transm 2003:1-26.
9. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.
10. Diniz BS, Pinto Júnior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 2008;9:172-82.
11. Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, et al. Biomarkers in the cerebrospinal f uid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease. [In Spanish]. Rev Neurol 2010;50:193-200.
12. Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 2009;80:966-75.
13. Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34.
14. Fellgiebel A, Scheurich A, Bartenstein P, et al. FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res 2007;155:167-71.
15. Herukka SK, Hallikainen M, Soininen H, et al. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294-7.
16. Ewers M, Buerger K, Teipel SJ, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69:2205-12.
17. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]f uoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-71.
18. Arnáiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12:851-5.
19. Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 1996;802:70-8.
20. Bottino CM, Almeida O P. Can neuroimaging techniques identify individuals at risk of developing Alzheimer's disease? Int Psychogeriatr 1997;9:389-403.
21. Okamura N, Arai H, Maruyama M, et al. Combined analysis of CSF tau levels and [(123)I]iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's Disease. Am J Psychiatry 2002;159:474-6.
22. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-40.
23. Borroni B, Anchisi D, Paghera B, et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 2006;27:24-31.
24. Hansson O, Buchhave P, Zetterberg H, et al. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009;30:165-73.
25. Devanand DP, Liu X, Tabert MH, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 2008;64:871-9.
26. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-27.
27. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-6.
28. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. J Neurol Neurosurg Psychiatry 2006;77:714-8.